Neunburg, Germany

Christian Lottner


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christian Lottner: Innovator in Tumor Treatment

Introduction

Christian Lottner is a notable inventor based in Neunburg, Germany. He has made significant contributions to the field of medical science, particularly in the development of innovative compounds for tumor treatment. His work focuses on enhancing the effectiveness of therapies for both benign and malignant tumor diseases.

Latest Patents

Lottner holds a patent for "Water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases." This invention relates to novel, water-soluble porphyrin platinum compounds, specifically tetraarylporphyrin platinum derivatives and hematoporphyrin platinum derivatives. These compounds exhibit high tumor selectivity and are particularly suitable for photodynamic anti-tumor therapy. He has 1 patent to his name.

Career Highlights

Christian Lottner is associated with Zentaris GmbH, where he continues to work on groundbreaking research in the field of oncology. His innovative approach to developing water-soluble compounds has the potential to revolutionize treatment methods for tumor diseases.

Collaborations

Lottner collaborates with esteemed colleagues such as Karl Christian Bart and Guenther Bernhardt. Their combined expertise contributes to the advancement of research and development in tumor therapies.

Conclusion

Christian Lottner's contributions to medical science, particularly in the area of tumor treatment, highlight his role as an influential inventor. His innovative compounds pave the way for more effective therapies, showcasing the importance of research in improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…